Search
Metoclopramide
go.drugbank.com/drugs/DB01233ApprovedInvestigationalIt is available in the oral tablet form or in solution, and can also be administered through the intravenous route.[T683] Metoclopramide was initially approved by the FDA in 1980.[A184922]
Cisatracurium
go.drugbank.com/drugs/DB00565ApprovedInvestigationalCisatracurium is a non-depolarising neuromuscular blocking agent of the benzylisoquinolinium class, available in its salt form, cisatracurium besylate. … This action is antagonized by acetylcholinesterase inhibitors such as neostigmine.
Catridecacog
go.drugbank.com/drugs/DB09310ApprovedCoagulation Factor XIII A-Subunit (Recombinant) is available in the US as the commmercially available product Tretten, and in the EU as NovoThirteen. … Also known as Fibrin Stabilizing Factor (FSF), Factor XIII is an endogenously available coagulation factor and the final enzyme within the blood coagulation cascade.
Pibrentasvir
go.drugbank.com/drugs/DB13878ApprovedInvestigationalPibrentasvir is available as an oral combination therapy with [DB13879] under the brand name Mavyret. … Mavyret is also indicated for HCV genotype 1-infected patients who have been previously treated with regimens either containing an NS5A inhibitor or an NS3/4A protease inhibitor, but not both [L940].
Efmoroctocog alfa
go.drugbank.com/drugs/DB11607ApprovedInvestigationalIn animal models of haemophilia, efmoroctocog alfa demonstrated an approximately two-fold longer t½ than commercially available rFVIII products [A31551]. … Efmoroctocog alfa is a first commercially available rFVIII-Fc fusion protein (rFVIIIFc) where the conjugated molecule of rFVIII to polyethylene glycol is covalently fused to the dimeric Fc domain of human
Hydroxyzine
go.drugbank.com/drugs/DB00557ApprovedInvestigational[L9677] The active metabolite of hydroxyzine, [cetirizine], is also available as an active ingredient in allergic medications, and is responsible for much of its hydroxyzine's antihistaminic effect. … [A189753] Hydroxyzine is also used for generalized anxiety disorder, tension caused by psychoneurosis, and other conditions with manifestations of anxiety.[L9677]
Scopolamine
go.drugbank.com/drugs/DB00747ApprovedInvestigational[A228773, L31578] Scopolamine was first approved by the FDA on December 31, 1979, and is currently available as both oral tablets and a transdermal delivery system.[L31578] … [A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient than extracting scopolamine from plants.
Tradipitant
go.drugbank.com/drugs/DB12580ApprovedInvestigational[A275353] Approved by the FDA on December 30, 2025, tradipitant is indicated for the prevention of vomiting induced by motion.
Bulevirtide
go.drugbank.com/drugs/DB15248ApprovedInvestigational[A226340,L30235] Until recently, there have been extremely limited treatments available for Hepatitis D infection. … It was first approved for use in the EU on May 28, 2020; bulevirtide has been granted PRIME scheme eligibility and Orphan Drug Designation by the European Medicines Agency.
Belinostat
go.drugbank.com/drugs/DB05015ApprovedInvestigationalIntravenous administration of the agent is available as Beleodaq as monotherapy and the dosing regimen involves a 21-day cycle. … It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget.